Beverage industry relies on enzymatic PET recycling from CARBIOS
New purchase agreements bring French biotech company closer to production launch
Advertisement
CARBIOS has announced the signing of two further multi-year commercial agreements for the supply of recycled PET (r-PET) with leading companies in the Beverage Industry.
The signing of these two commercial agreements gives CARBIOS access to the strategically important beverage sector. These new commercial agreements are part of the pre-marketing strategy for CARBIOS' future industrial recycling plant, which is now operating at around 50% capacity.
Negotiations are currently underway with other partners to achieve 70% capacity utilization at the Longlaville site. This is one of the prerequisites for securing the additional undiluted funds required to resume construction of the Longlaville plant.
In addition, a regional funding agreement of €12.5 million has been signed, bringing the total public funding already secured to €42.5 million.
Vincent Kamel, CEO of CARBIOS: "These new agreements confirm the robustness of our technology and the attractiveness of our offering to key sectors such as the beverage industry. They are also proof that we are implementing our strategy of spreading our commercialization activities across a wide range of sectors."
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Gempex and msg industry advisors cooperate in the field of AI-supported services in the GMP-regulated environment - Quality assurance more efficient, targeted and secure
Tacalyx appoints Jean Engela as Chief Executive Officer for the next phase of growth
NextPharma sells its logistics division to Cencora - The sale is part of the plan to position NextPharma as Europe's leading pure-play CDMO.
How an Invisible “Cap” could control Electrical Synapses - New Building Blocks of Cell Communication
A new tunable cell-sorting device with potential biomedical applications - Precise, label-free sorting of cells of various sizes possible due to a temperature-sensitive PNIPAM hydrogel array
Proteins in a crowd: European XFEL looks inside cells - Researchers observe in detail how the vital iron protein ferritin makes its way in highly dense environments
The smell of fatty foods during pregnancy promotes obesity in offspring - The brains of the offspring show similarities to those of obese adult mice
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions - Collaboration combines complementary scientific and technical expertise to provide seamless solutions along the entire biopharmaceutical value chain
The power of gut enzymes: why a healthy diet works differently for everyone
Intelligent hydrogel microstructures enable the precise application of force to cellular systems